Join the Oncology Voice Network. Join for Free
How to leverage KOL relationships to achieve strategic objectives with Dr. Aoife O'Dwyer
MSL Consultant KOL relationships strategic objectives stakeholder mapping Pharma practices

How to leverage KOL relationships to achieve strategic objectives with Dr. Aoife O'Dwyer


Share This Article


Summary

My guest today is Aoife O Dwyer, Founder of MSL Consultant, and we discuss how to leverage KOL relationships to achieve strategic objectives.

In this episode:

  • What made Aoife decide to become an MSL Consultant and what she likes best about her role
  • Aoife’s advice to MSLs who want to demonstrate their value to their company
  • Most important things for people to remember in KOL identifications and stakeholder mapping
  • Tips on getting a KOL meeting
  • How can an MSL deliver value in a KOL meeting
  • How can an MSL plan for a KOL meeting
  • How has COVID affected an MSL’s ability to provide value and what advice Aoife can give to MSLs in handling this crisis
  • What skills are now mandatory for MSLs during and after the COVID crisis to provide value to their KOLs and to their organization
  • How Aoife expects Pharma to change practices as a result of Covid-19
  • Advice to MSLs to help aid in their success

Click for Source
MSL Consultant, KOL relationships, strategic objectives, stakeholder mapping, Pharma practices

Related Topics

Meet Our Innovation Partners

Loading partners...

You May Also Like

Podcast
How to Build Scientific Credibility for Continuous Career Development
Partner Avatar MSL Talk: Tom Caravela, Ike Ogbaa

How to Build Scientific Credibility for Continuous Career Development

Podcast
What I DO….How I BUILD Relationships
Partner Avatar MSL Talk: Tom Caravela, Bernadett Mamone

What I DO….How I BUILD Relationships

Article
Value assessment of oncology drugs using a weighted criterion-based approach
OVN Avatar Doreen A. Ezeife MD, Francois Dionne PhD, Aline Fusco Fares MD, Ellen Laura Rose Cusano MD, Rouhi Fazelzad BSc, MISt, Wenzie Ng BSc, MPharm, RPh, Don Husereau BSc Pharm, MSc, Farzad Ali BPharm, MSc, Christina Sit MSc, Barry Stein B.Com BCL, LLB, Jennifer

Value assessment of oncology drugs using a weighted criterion-based approach

Article
Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects
OVN Avatar Haiqing Isaac Dai, Yulia Vugmeyster, Naveen Mangal

Characterizing Exposure–Response Relationship for Therapeutic Monoclonal Antibodies in Immuno-Oncology and Beyond: Challenges, Perspectives, and Prospects

Article
Outcome measures for oncology alternative payment models: practical considerations and recommendations
OVN Avatar Jakub P. Hlávka, PhD, Pei-Jung Lin, PhD, Peter J. Neumann, ScD

Outcome measures for oncology alternative payment models: practical considerations and recommendations

Article
Leveraging existing data to contextualize phase II clinical trial findings in oncology
OVN Avatar E.M. Ray, L.A. Carey, K.E. Reeder-Hayes

Leveraging existing data to contextualize phase II clinical trial findings in oncology

Explore OVN